Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment"

Antimicrob Agents Chemother. 2017 May 24;61(6):e00427-17. doi: 10.1128/AAC.00427-17. Print 2017 Jun.

Authors

M O Fofana¹, D W Dowdy²

Affiliations

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA [email protected].

No abstract available

Publication types

Comment

MeSH terms

Antitubercular Agents
Humans
Microbial Sensitivity Tests
Mycobacterium tuberculosis
Pyrazinamide*
Tuberculosis, Multidrug-Resistant*

Substances

Antitubercular Agents
Pyrazinamide

Grants and funding

T32 GM007309/GM/NIGMS NIH HHS/United States